Glitisol

Glitisol is a prescription oral medication that contains the active ingredient glibenclamide, a second‑generation sulfonylurea. It is marketed in the European Union and is supplied in tablet form for systemic use. Glibenclamide works by stimulating insulin release from pancreatic beta cells, helping to lower blood glucose levels in adults with type 2 diabetes mellitus.

Glitisol is indicated for the management of type 2 diabetes mellitus when diet, exercise, and other oral agents are insufficient. It is used as part of a comprehensive diabetes care plan.

- Improves glycemic control in adults with type 2 diabetes. - Can be combined with metformin or other antidiabetic agents. - May be used when lifestyle modifications alone do not achieve target glucose levels. - Intended for patients with preserved pancreatic beta‑cell function. - Often prescribed after other oral hypoglycemics have been tried.

Glitisol may cause a range of side effects, most of which are mild and transient. Serious adverse reactions are less common but require medical attention.

Common: - Hypoglycemia (low blood sugar) - Nausea or abdominal discomfort - Headache - Dizziness - Weight gain - Skin rash or itching

Serious: - Severe hypoglycemia leading to loss of consciousness - Allergic reactions such as angioedema - Hepatotoxicity (liver injury) - Hematologic abnormalities (e.g., leukopenia)

Before starting Glitisol, certain health considerations should be reviewed to ensure safe use.

- Assess renal and hepatic function, as impairment may require dose adjustment. - Use caution in elderly patients due to increased risk of hypoglycemia. - Avoid use during pregnancy and lactation unless clearly indicated by a physician. - Monitor blood glucose regularly to detect hypoglycemia early. - Patients with a history of cardiovascular disease should be evaluated for risk. - Discontinue if signs of severe allergic reaction appear.

Glitisol can interact with several medicines, affecting its efficacy or safety profile.

Avoid: - Other sulfonylureas or insulin secretagogues (risk of additive hypoglycemia). - Strong CYP2C9 inhibitors such as fluconazole or amiodarone (may increase glibenclamide levels). - MAO inhibitors (potential for enhanced hypoglycemic effect).

Use with caution: - Beta‑blockers (may mask hypoglycemia symptoms). - Thiazide diuretics (can affect glucose control). - Anticoagulants like warfarin (possible alteration of INR). - NSAIDs (may increase risk of renal impairment).